Celcuity is a clinical-stage, publicly traded biotechnology company dedicated to extending the lives of cancer patients through the development of targeted therapies for various solid tumor indications. Founded with the mission to improve treatment for the cellular drivers of tumor growth, Celcuity is advancing its lead therapeutic candidate, gedatolisib, a potential first-in-class PI3K/AKT/mTOR pathway inhibitor. The company is focused on innovative clinical development programs, including phase 3 trials for HR+/HER2- advanced breast cancer and ongoing studies for metastatic castration-resistant prostate cancer. Committed to fair compensation and equal opportunity, Celcuity offers competitive total compensation packages and a range of employee benefits.